Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVICONTROL-1
2011-004235-31Phase 3Completed
- Sponsor
- IPPMed
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olmesartan and amlodipine in essential hypertension (2 arms), sponsored by IPPMed. Primary endpoint: Daytime systolic ABPM reduction after switch to olmesartan + amlodipine. Started Sep 2011; status: completed.
02
Drugs
olmesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2011-004235-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004235-31.